ASCO 22: Promising early data for next-gen CAR T-cell therapy

27 May 2022

A new kind of therapy which raises the prospect of an off-the-shelf approach to CAR T-cell treatment has scored an early-stage win, lifting shares in developer Adicet Bio (Nasdaq: ACET).

The Californian firm is developing ADI-001, a gamma-delta T-cell therapy which generated positive top-line data in late 2021, showing three of the four lymphoma patients treated went into remission.

Now, ahead of the annual meeting of the American Society of Clinical Oncology (ASCO 22), the company has provided further data, up to the ASCO cut-off point of February 14.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK